Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease

17/02/20

DOWNLOAD

Oncodesign announces a 33% revenue increase in 2019 and the achievement of financial breakeven one year ahead of schedule

20/01/20

DOWNLOAD